LOXO-292 (Selpercatinib, LOXO 292, LOXO292) is a potent, selective, orally available RET kinase inhibitor with potential antineoplastic activity; displays >100-fold selectivity versus important off-targets; shows anti-tumor activty in the brain and periphery in RET-dependent tumor models in vivo.Lung Cancer
Reference:
[1]. Subbiah V, et al. Ann Oncol. 2018 Aug 1;29(8):1869-1876.
[2]. Cancer Discov. 2018 Aug;8(8):904-905.
















